Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adult Wilms' tumor: a case report

M Orditura1, F De Vita, G Catalano

  • 1Department of Internal and Experimental Medicine F. Magrassi, II University of Naples School of Medicine, Italy.

Cancer
|November 20, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>HER-2</i> gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study.

ESMO gastrointestinal oncology·2026
Same author

Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancer.

ESMO gastrointestinal oncology·2026
Same author

Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approach.

ESMO real world data and digital oncology·2026
Same author

Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy.

ESMO open·2025
Same author

Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial.

ESMO open·2025
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
Same journal

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
See all related articles

Adult Wilms' tumor is rare, but aggressive multimodal therapy including chemotherapy with agents typically used for recurrent disease showed significant activity in an advanced case. Further investigation of this treatment schedule is warranted.

Area of Science:

  • Oncology
  • Nephrology
  • Cancer Therapeutics

Background:

  • Adult Wilms' tumor is a rare malignancy with no established treatment guidelines.
  • Aggressive therapy involving surgery, radiotherapy, and chemotherapy is generally recommended.

Observation:

  • A case of advanced adult Wilms' tumor with hepatic and pulmonary metastases is presented.
  • The patient underwent nephrectomy followed by combination chemotherapy (carboplatin, etoposide, ifosfamide, epirubicin) and irradiation.

Findings:

  • The multimodal treatment demonstrated impressive activity, with no evidence of metastatic disease 41 months post-treatment.
  • High but manageable hematologic toxicity was observed, requiring supportive care.

Implications:

Related Experiment Videos

  • This case suggests that a chemotherapeutic regimen with agents typically used for recurrent disease may be effective in advanced adult Wilms' tumor.
  • Further investigation into this alternative treatment schedule is recommended for this rare cancer.